- Home
- COF vs GSK Comparison
COF vs GSK Comparison
Compare COF & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COF | GSK |
|---|---|---|
| Founded | 1988 | 1715 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.8B | 96.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | COF | GSK |
|---|---|---|
| Price | $186.95 | $54.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 2 |
| Target Price | ★ $269.31 | N/A |
| AVG Volume (30 Days) | 4.8M | ★ 5.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | 1.65% | ★ 3.17% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $96.05 | $6.81 |
| Revenue Next Year | $4.97 | $4.74 |
| P/E Ratio | $52.03 | ★ $32.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $143.22 | $32.38 |
| 52 Week High | $259.64 | $61.70 |
Technical Indicators
Market Signals| Indicator | COF | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 32.98 | 40.77 |
| Support Level | N/A | $47.89 |
| Resistance Level | $226.76 | $60.37 |
| Average True Range (ATR) | 7.04 | 0.86 |
| MACD | -0.66 | -0.89 |
| Stochastic Oscillator | 11.37 | 6.29 |
Price Performance
Historical ComparisonAbout COF Capital One Financial Corporation
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending. Following the acquisition of Discover in 2025, the firm also has a modest personal loan business, though credit card lending provides the majority of the bank's revenue.
About GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.